Shots:
- Sinovent & SinoMab to receive $12M up front, ~$549M in development, regulatory & commercial milestone along with royalties on net sales of a product
- The agreement will strengthen Everest’s leadership in developing novel therapies for renal disease in Greater China & Asia. The agreement also includes technology transfer of manufacturing process to Everest for the development & commercialization of the product
- XNW1011 is a covalent reversible BTK inhibitor that exhibits high selectivity, PK, robust target engagement & safety profile to support the development based on results from the P-I study. Everest also plans to initiate a P-II trial of XNW1011 for the same indication
Click here to read full press release/ article | Ref: Everest | Image: PR Newswire
The post Everest Enter into an Exclusive License Agreement with Sinovent and SinoMab to Develop and Commercialize XNW1011 for Renal Diseases first appeared on PharmaShots.
